Key positives include a long operating history and strong brand in critical hospital and renal therapies, a diversified portfolio that spans devices, pharmaceuticals, and connected care, and a global footprint with deep customer relationships. The company has been deliberately reducing debt and improving liquidity, which strengthens its resilience despite recent setbacks. Its ongoing R&D efforts and focus on connected care, smart hospital solutions, and differentiated injectables provide clear strategic avenues for future growth. Customer switching costs and integrated platforms give Baxter a modest but meaningful competitive edge.

Major concerns center on the volatility and quality of earnings and cash flows, with recent years showing weak or negative operating margins and a sharp drop‑off in operating and free cash generation. Repeated asset write‑downs and declining retained earnings highlight past missteps and reduced cumulative profitability. Competitive and pricing pressures in medtech and dialysis, coupled with rapid technological change, add external risk, while integration and restructuring efforts add internal execution risk. If cash flow does not recover, Baxter may face tougher choices on how much it can invest, deleverage, and return to shareholders at the same time.

Baxter appears to be in a multi‑year transition: cleaning up its balance sheet, reshaping its portfolio toward connected care and specialized therapies, and trying to restore sustainable profitability. The improved leverage and liquidity provide a better foundation, but the recent collapse in cash generation and fragile operating margins keep uncertainty high. If management can stabilize the core business, control costs, and successfully commercialize its innovation pipeline, the company’s strategic assets could support a more reliable earnings profile. Until that happens, the financial picture looks mixed—strategically promising but operationally and financially uneven.